Calamos Advisors LLC
- SEC CIK
- 0001316507
- Latest filing
- Jul 31, 2026
ENGNW holding history
enGene Therapeutics Inc. in every 13F filed by Calamos Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ENGNW overviewAll 13F holders of ENGNWFull Q2 2026 holdings
- Shares (Q1 2026)
- 0
- Sold out in Q1 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q4 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2026 | 0 | $0 | 0.0% | −148,290−100.0% | Sold out | Holders |
| Q4 2025 | 148,290 | $418.2K | <0.1% | −1,710−1.1% | Reduced | Holders |
| Q3 2025 | 150,000 | $108.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2025 | 150,000 | $118.3K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2025 | 150,000 | $96.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2024 | 150,000 | $127.5K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 150,000 | $213.8K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 150,000 | $208.5K | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 150,000 | $780.0K | <0.1% | −100,000−40.0% | Reduced | Holders |
| Q4 2023 | 250,000 | $212.5K | <0.1% | +250,000 | New | Holders |